PLX Stock Price, Chart, Stats & News
Protalix BioTherapeutics, Inc. (PLX) does not currently pay a dividend.
PLX chart
Fundamentals
Gross margin | 48.82% |
Operating margin | -10.43% |
Pretax margin | -10.63% |
Net margin | -12.52% |
Effective tax rate | -17.76% |
ROA | -8.02% |
ROE | -13.46% |
D/E | 0.17x |
Interest coverage ratio | -4.62x |
PLX valuation
P/E | 12.37x |
P/S | 3.27x |
P/B | 3.49x |
P/CF | -14.02x |
P/FCF | -14.38x |
P/OCF | -14.02x |
PEG | 0.12x |
EV multiple | -44.31x |
About
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
Similar securities
Based on sector and market capitalization
